Compare SKIL & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKIL | KPTI |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.2M | 47.6M |
| IPO Year | 2019 | 2013 |
| Metric | SKIL | KPTI |
|---|---|---|
| Price | $7.70 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | 47.4K | ★ 2.4M |
| Earning Date | 04-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | $0.11 | N/A |
| Revenue Next Year | N/A | $22.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $3.43 | $1.79 |
| 52 Week High | $18.45 | $10.99 |
| Indicator | SKIL | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 20.75 |
| Support Level | $6.18 | N/A |
| Resistance Level | $8.34 | $2.18 |
| Average True Range (ATR) | 0.82 | 0.24 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 26.57 | 3.02 |
Skillsoft Corp is a leader in corporate digital learning. The company's segments include Talent Development Solutions and Global Knowledge. Talent Development Solutions brings a foundation of products and customers. TDS enterprise-grade solution serves customers and employees world-wide. TDS Learner is a world-renowned consumer-scale and experiential learning platform that serves learners internationally. The Global Knowledge segment is centered around instructor-led training, or live learning, with face-to-face delivery by experienced trainers, both in-person and virtually.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).